209 related articles for article (PubMed ID: 23033982)
1. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study.
Kim KC; Yook JH; Eisenbraun J; Kim BS; Huber R
BMC Complement Altern Med; 2012 Oct; 12():172. PubMed ID: 23033982
[TBL] [Abstract][Full Text] [Related]
2. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
Pelzer F; Tröger W; Nat DR
J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
4. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
[TBL] [Abstract][Full Text] [Related]
5. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
7. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects.
Huber R; Lüdtke H; Wieber J; Beckmann C
BMC Complement Altern Med; 2011 Nov; 11():116. PubMed ID: 22114899
[TBL] [Abstract][Full Text] [Related]
8. [Mistletoe in the treatment of cancer patients].
Rostock M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
[TBL] [Abstract][Full Text] [Related]
9. [Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients].
Steuer-Vogt MK; Bonkowsky V; Scholz M; Fauser C; Licht K; Ambrosch P
HNO; 2006 Apr; 54(4):277-86. PubMed ID: 16132877
[TBL] [Abstract][Full Text] [Related]
10. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
11. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador).
Gorter RW; van Wely M; Stoss M; Wollina U
Am J Ther; 1998 May; 5(3):181-7. PubMed ID: 10099057
[TBL] [Abstract][Full Text] [Related]
13. Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.
Bar-Sela G; Haim N
Med Oncol; 2004; 21(3):251-4. PubMed ID: 15456952
[TBL] [Abstract][Full Text] [Related]
14. Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks.
Stoss M; van Wely M; Musielsky H; Gorter RW
Arzneimittelforschung; 1999 Apr; 49(4):366-73. PubMed ID: 10337457
[TBL] [Abstract][Full Text] [Related]
15. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
Piao BK; Wang YX; Xie GR; Mansmann U; Matthes H; Beuth J; Lin HS
Anticancer Res; 2004; 24(1):303-9. PubMed ID: 15015612
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
Melzer J; Iten F; Hostanska K; Saller R
Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
[TBL] [Abstract][Full Text] [Related]
17. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
Büssing A
Arzneimittelforschung; 2006 Jun; 56(6A):508-15. PubMed ID: 16927532
[TBL] [Abstract][Full Text] [Related]
18. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
Grossarth-Maticek R; Ziegler R
Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
[TBL] [Abstract][Full Text] [Related]
19. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
[TBL] [Abstract][Full Text] [Related]
20. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
Schad F; Axtner J; Kröz M; Matthes H; Steele ML
Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
